The proliferative activity of neoplastic plasma cells (PCs) is an independent determinant of the clinical course of patients with multiple myeloma (MM). It can be measured by the plasma cell labeling index (PCLI), which denotes the percentage of bone marrow PCs in the S-phase of the cell cycle. 1 Typically, MM is a slow-growing tumor with very few PCs synthesizing DNA at a given time. Proliferative myeloma, characterized by a high PCLI (X1%), constitutes nearly a third of all MM cases, and has a poorer outcome. 1 Although technical difficulties have limited its widespread application, the slide-based PCLI provides valuable insight into the tumor biology, with higher PCLI predictive of an aggressive course. [1] [2] [3] There is a direct correlation between the cytogenetic abnormalities and the rate of PC division perhaps because these chromosomal abnormalities impart a distinct proliferative advantage to the myeloma cells. 4 Conversely, it can be argued that rapid PC division leads to sufficient genetic instability to cause secondary chromosomal abnormalities, which adversely affect the prognosis of the patients.
Both conventional chemotherapies and more aggressive approaches such as high-dose therapy and autologous stem cell transplantation fail to alter the inherently aggressive behavior of highly proliferative myeloma. 5 Whether the integration of novel immunomodulatory therapies to the treatment paradigm of newly diagnosed MM favorably modifies the clinical course of such patients remains unknown.
We determined the impact of thalidomide-dexamethasone (Thal-Dex) or lenalidomide-dexamethasone (Len-Dex) therapy on proliferative MM by reviewing data from 125 newly diagnosed, previously untreated MM patients enrolled in clinical trials of either thalidomide (200 mg per day) plus dexamethasone (40 mg per day on days 1-4, 9-12 and 17-20 in odd cycles and days 1-4 in even cycles; n ¼ 50) or lenalidomide (25 mg per day on days 1-21 of a 4-week cycle) plus dexamethasone (40 mg per day on days 1-4, 9-12,17-20 or 40 mg/week in each 28-day cycle; n ¼ 75) as initial therapy. 6, 7 The participants could go off studies after 4 cycles of therapy to pursue stem-cell harvest and autologous stem cell transplantation. The proliferative rate of PCs was assessed by measuring the PCLI by the previously described slide-based immunofluorescent bromodeoxyuridine method. 1 The international uniform response criteria were applied to define disease progression.
Patients were categorized into two groups based on the PCLI: high PCLI group (PCLI X1%) or low PCLI group (PCLI o1%). We used this cutoff based on our previous studies, which consistently demonstrated poorer outcome with PCLI exceeding this value. 1 Overall survival (OS) was defined as the time from registration to death from any cause, and progression-free survival (PFS) was defined as the time from registration to the earlier of the first documentation of progression or death from Table 1 Baseline patient characteristics by PCLI groupings Letters to the Editor any cause. The distributions of PFS and OS were estimated using the Kaplan-Meier method. Univariate Cox proportional hazards model was used to explore the impact of baseline PCLI on OS and PFS.
The median follow-up for patients on Thal-Dex and Len-Dex was 7.5 years and 3 years, respectively. The baseline patient characteristics were similar between the two studies. The median PFS and OS for patients on Thal-Dex were 1.7 years (95% confidence interval: 1.3-2.4) and 4.7 years (95% confidence interval: 3.1-8.1), respectively. The median PFS for patients on Len-Dex was 2.6 years (95% confidence interval: 1.8-3.1) and the median OS is not yet reached. Thirty-six percent (18 out of 50) of patients in the Thal-Dex study and 35 percent (26 out of 75) in the Len-Dex study had a high PCLI. The distribution of the baseline patient characteristics within the two PCLI groups for each study and the outcome data are presented in Table 1 and Figure 1 , respectively. In the Thal-Dex group, patients with PCLI X1% demonstrated inferior PFS (1.3 years vs 2.3 years; P ¼ 0.01) and OS (2.3 years vs 6.9 years; P ¼ 0.03). With Len-Dex, no significant difference in outcome measures was observed between the PCLI groups. Due to a shorter median follow-up of Len-Dex patients, a separate analysis, reviewing the 3-year survival was performed for all patients in both studies, and the results were similar.
Our findings indicate that the proliferative rate of myeloma cells remains a significant determinant of outcome in newly diagnosed patients treated with Thal-Dex. This regimen has resulted in high overall response rates compared with conventional agents in several studies. 7 However, our analysis demonstrates its inability to overcome the adverse impact of high proliferative activity. These results are in concordance with the findings of previous studies with conventional chemotherapy and autologous stem cell transplantation in which patients with highly proliferative tumors exhibited poorer survival. [1] [2] [3] In contrast, during the first 3 years of follow-up, the unfavorable effect of PCLI using a cutoff of 1% is not apparent with Len-Dex, which has demonstrated higher overall response rate in recent trials. 6 The ability of lenalidomide to affect the outcome of proliferative MM may be a function of the depth of response seen with this agent, as reduction of a clone to very low levels can conceivably prevent or slow the development of resistant clones.
We utilized data from the earliest trials conducted at our institution with immunomodulatory therapies in order to study the long-term outcome of rapidly proliferating MM. We recognize that the doses of thalidomide and dexamethasone used in those trials have fallen out of favor for the more appropriate, reduced doses with less toxicity, but this should not impact the results seen here.
A high proliferative rate is but one marker of high-risk MM although it correlates well with other prognostic markers such as cytogenetic abnormalities and elevated B2M. Our current findings must be taken in the context of another recent study by our group, demonstrating that patients with high-risk MM, defined by the presence of certain genetic abnormalities and/or an extremely high PCLI (X3%) do not derive the same degree of benefit with upfront Len-Dex as do the standard-risk patients. 8 Thus, the prognostic effect of PCLI is dependent on the specific level of cutoff used. A higher PCLI cutoff of X3% identifies a small proportion (o10%) of patients with markedly high proliferation, and particularly aggressive disease, and remains an adverse prognostic feature even with Len-Dex therapy. 8 This subset of patients requires further studies with agents such as bortezomib which appears to overcome the adverse prognostic effects of certain chromosomal abnormalities. It is possible that with Len-Dex the difference in outcome, particularly in the PFS between the two PCLI groups will become evident with time; although a 3-year period could arguably be considered sufficiently long to evaluate the impact of rapidly proliferating tumors with typically reduced OS. 3) for patients with low PCLI, (HR ¼ 2.2; P ¼ 0.01). No significant difference in PFS was observed between the two groups receiving Len-Dex; median PFS was 2.3 years (95% CI: 1.4-3.1) for patients with high PCLI and 3.1 years (95% CI: 1.8-3.6) for patients in the low PCLI group (HR ¼ 1.3; P ¼ 0.32). (b) For patients receiving Thal-Dex, the median OS was 2.3 years (95% CI: 1.3-4.6) in the high PCLI group compared with 6.9 years (95% CI: 3.9-NA) for low PCLI (HR ¼ 2.2; P ¼ 0.03). The median OS for patients on Len-Dex was not attained by either high or low PCLI group (HR ¼ 1.2; P ¼ 0.80).
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